Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
Syndax Pharmaceuticals has 12 abstracts accepted for presentation at the EHA 2026 Congress, showcasing the strong clinical activity of Revuforj (revumenib) across various stages of acute leukemia treatment. The abstracts highlight favorable outcomes and tolerability with revumenib, particularly in the post-transplant setting and in combination with other therapies. This reinforces the drug's potential and the company's leadership in menin inhibition.
Key figures
- Drug Name
- Revuforj (revumenib)
- Phase Of Trial
- Phase 1, Phase 1/2, Phase 3
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.